SciSparc Ltd. , a specialty, clinical-stage pharmaceutical company based in Israel, is staying true to their goal of developing therapies for the — treatment of disorders of the central nervous system, with the announcement of a planned expansion of their partners’ network. In a related development, the company looks ready to spread their tentacles into new regions, including North America, helping more people stay healthy and happy.
"Looking forward to 2022, we are aiming to show progress in our clinical programs in Tourette Syndrome (TS), Alzheimer's disease (AD) and Agitation and Autism Spectrum Disorder (ASD). We are planning on expanding our partners' network and continuing to raise awareness of our unique technologies and novel treatments by showcasing them in leading events worldwide. We plan on strengthening our professional team and advisory board as well as increasing exposure to investors in North America," said Amitai Weiss, Chief Executive Officer of SciSparc.
A United Nations report stated that nearly one in six of the world’s population suffers from neurological disorders, such as Alzheimer's and Parkinson's disease, strokes, multiple sclerosis, and epilepsy to migraine, brain injuries, and neuro-infections. It also stated that about 6.8 million people die of the maladies yearly. Over the years, a plethora of treatment options have been developed to help patients with CNS disorders. However, the team at SciSparc Ltd. as led by Amitay Weiss seeks to take the experience a notch higher as substantiated by the plans to expand to more parts across the globe.
SciSparc Ltd. offers platforms primarily designed to focus on the endocannabinoid system, with a blend of FDA – approved and New Chemical Entities (NCEs) and a combination of cannabinoids and n-acylethanolamines, to deliver treatments for targeted conditions that either lack or have insufficient effective therapies. The company has developed novel therapies that have demonstrated heightened bioavailability, significant improvement in efficacy, better safety profiles, reduced side effects, and lower dosage requirements.
Products from SciSparc Ltd. include the SCI-110, SCI-210, SCI-160, and CannAmide™, an immediate unique palmitoylethanolamide (PEA) oral formulation for the reduction of chronic pain and inflammation. SciSparc Ltd. has already achieved giant strides in a relatively short while, completing a corporate rebranding in 2021 and subsequently listing its ordinary shares on the Nasdaq Capital Market. It was also able to raise over $8 million in a private placement during the same year, receiving two patents from the Australian Patent Office and one from the Japanese Patent Office.
For more information about SciSparc Ltd. and their revolutionary treatments for central nervous system disorders, visit - https://scisparc.com/. SciSparc Ltd. can also be found across social media, including Facebook and LinkedIn.
Release ID: 89058664